Compare Domino's Pizza, Inc. (DPZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Summit Therapeutics Inc — how do they compare? Domino's Pizza, Inc. trades at $353.5 (market cap $11.82B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Domino's Pizza, Inc. and Summit Therapeutics Inc are close in size by market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DPZ | SMMT | |
|---|---|---|
Market Cap | $11.82B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $26.98 |
52-Week Low | $282.89 | $12.55 |
Enterprise Value | $16.78B | $11.39B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $353.72, up 1.69% today, with a bullish technical signal from moving averages and support at $352. Revenue grew to $4.94B in 2025, with net income of $601.70M, though recent quarters saw EPS misses. The company launched a new individual pizza product in August 2026 to boost sales, as reported by WSJ on August 11, 2026.
Outlook is mixed: analyst consensus is a Buy with a $371.67 target, but high debt and weak Q3 2026 EPS expectations pose risks. Growth depends on new product success and cost management amid competitive pressures.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
